Clinical manifestations and outcome of SARS-CoV-2 infections in children and adolescents with rheumatic musculoskeletal diseases: data from the National Paediatric Rheumatology Database in Germany

Article activity feed

1. Version published to 10.1136/rmdopen-2021-001687

   Jul 1, 2021
2. 

   ScreenIT

   Apr 2, 2021

   SciScore for 10.1101/2021.03.28.21254496: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Institutional Review Board Statement	IRB: The SARS-CoV-2 module of the NPRD was approved by the ethics committee of the Charité - Universitäsmedizin Berlin, as was the data collection of the BiKeR Registry and the DGPI Registry by their respective ethics committees.
   Randomization	not detected.
   Blinding	not detected.
   Power Analysis	not detected.
   Sex as a biological variable	not detected.

   Table 2: Resources

   Antibodies
   Sentences	Resources
   This item was evaluated only in individuals with a date of COVID-19 symptom onset, or – if asymptomatic – with a date of PCR or antigen testing, because these methods allowed to determine the point of time the disease/infection occurred (in contrast to antibody testing) To …

   SciScore for 10.1101/2021.03.28.21254496: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Institutional Review Board Statement	IRB: The SARS-CoV-2 module of the NPRD was approved by the ethics committee of the Charité - Universitäsmedizin Berlin, as was the data collection of the BiKeR Registry and the DGPI Registry by their respective ethics committees.
   Randomization	not detected.
   Blinding	not detected.
   Power Analysis	not detected.
   Sex as a biological variable	not detected.

   Table 2: Resources

   Antibodies
   Sentences	Resources
   This item was evaluated only in individuals with a date of COVID-19 symptom onset, or – if asymptomatic – with a date of PCR or antigen testing, because these methods allowed to determine the point of time the disease/infection occurred (in contrast to antibody testing) To determine whether the NRS values were reported in chronological order, i.e. the NRS timeline can be clearly separated into before/after SARS-CoV-2 infection, only valid dates were considered.	antigen testing, suggested: None
   Software and Algorithms
   Sentences	Resources
   Statistics: Statistical analyses were performed using IBM SPSS Statistics 26 and SAS 9.4M5.	SPSS suggested: (SPSS, RRID:SCR_002865)
   Plots were made with Microsoft Excel 2016.	Microsoft Excel suggested: (Microsoft Excel, RRID:SCR_016137)

   ---

   Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

   ---

   Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:

   Limitations: Our data collection was based on voluntary reporting of confirmed SARS-CoV-2 infections in juvenile patients with RMD and therefore likely does not include all such patients in Germany. The relatively small number of cases of each disease entity and the variety of therapies do not allow reliable conclusions regarding implications of a specific rheumatic disease or the effects of medication on the clinical expression and outcome of SARS-CoV-2 infection in these patients. Assessment of disease activity before and after SARS-CoV-2 infection was performed as part of routine clinical practice and not after a fixed interval. Therefore, it is possible that flares that occurred in the period after SARS-CoV-2 infection but before outcome assessment were not recorded. Furthermore, we did not have a comparison group of SARS-CoV-2-negative patients with RMD regarding the change in NRS of disease activity over a comparable period of time. Summary: In summary, the clinical characteristics of COVID-19 in this patient group are similar to those of healthy peers; disease course was mild with and without maintaining DMARD therapy and COVID- 19 outcome was good in most of these patients. Furthermore, SARS-CoV-2 infection does not appear to have a major effect on the underlying disease activity, whereas discontinuation of therapy might pose a risk of flare in patients with moderately active disease. To our knowledge, our cohort currently represents the largest collection of data fro...

   ---

   Results from TrialIdentifier: No clinical trial numbers were referenced.

   ---

   Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

   ---

   Results from JetFighter: We did not find any issues relating to colormaps.

   ---

   Results from rtransparent:

   • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
   • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
   • No protocol registration statement was detected.

   ---

   Read the original source
3. 

   Version published to 10.1101/2021.03.28.21254496v1 on medRxiv

   Mar 31, 2021